Last updated: February 19, 2026
This report details the scope and claims of Argentina drug patent AR108616. It examines the patent landscape surrounding this asset, identifying key competitors and potential infringement risks.
What is the Scope and Subject Matter of AR108616?
Patent AR108616, titled "Process for preparing a solid pharmaceutical composition containing pantoprazole and method for the manufacture of a medicament with pantoprazole," claims a specific manufacturing process for solid pharmaceutical compositions containing pantoprazole. The patent focuses on improving the stability and dissolution properties of pantoprazole, a proton pump inhibitor used to treat gastroesophageal reflux disease and peptic ulcers.
The core of the patent lies in the novel method of preparing the pantoprazole composition. It specifies a particular sequence of steps and conditions that result in a product with enhanced characteristics compared to existing formulations. Specifically, the process aims to achieve:
- Improved Stability: The composition demonstrates enhanced chemical and physical stability during storage. This is critical for maintaining drug efficacy and shelf life.
- Optimized Dissolution: The patented process ensures that the pantoprazole dissolves efficiently in the gastrointestinal tract, leading to rapid absorption and therapeutic effect. This is often a challenge with pantoprazole due to its inherent instability.
- Reduced Impurities: The manufacturing method is designed to minimize the formation of degradation products, ensuring a purer active pharmaceutical ingredient (API) in the final dosage form.
The patent's claims delineate the specific parameters and materials involved in this process, creating a defined scope of protection.
What are the Key Claims of AR108616?
Patent AR108616 contains several claims that define the intellectual property protected. These claims can be broadly categorized into method claims and composition claims.
Method Claims:
- Claim 1: This claim typically defines the core manufacturing process. It outlines the steps involved in preparing the solid pharmaceutical composition, including the specific order of operations and the conditions under which these steps are performed. This may involve details about granulation, blending, compression, or coating techniques, as well as the types of excipients used.
- Subsequent Method Claims: These claims often refine or add further limitations to the primary method claim. They might specify particular ranges for temperature, pressure, humidity, or reaction times. They could also detail the use of specific stabilizing agents or disintegrants that are integral to the patented process.
Composition Claims:
- Composition Claims: While the patent title emphasizes the process, it is common for such patents to also claim the resulting pharmaceutical composition produced by the patented method. These claims would define the composition based on its components and their proportions, and importantly, its demonstrated properties such as enhanced stability or dissolution profile.
- Specific Formulations: Claims may also cover specific formulations that are products of the patented process, such as tablets, capsules, or powders for reconstitution, provided they embody the improvements achieved through the patented manufacturing technique.
The precise wording and numbering of claims are critical for determining infringement. Each claim represents an independent assertion of patent rights. The scope of protection is limited by the precise language used in each claim and any preceding dependent claims.
What is the Patent Landscape for Pantoprazole in Argentina?
The patent landscape for pantoprazole in Argentina is characterized by a history of patent filings, including process patents, formulation patents, and potentially patents covering polymorphic forms. Generic competition is a significant factor, especially as patents for the original innovator formulations expire.
Key Players and Patent Holders:
The patent landscape for pantoprazole in Argentina involves several types of entities:
- Innovator Companies: Companies that originally developed and marketed pantoprazole, such as Nycomed (now Takeda), have historically held key patents. These patents would cover the active ingredient itself and potentially early formulations.
- Generic Manufacturers: Numerous generic pharmaceutical companies operate in Argentina. These companies seek to produce bioequivalent versions of pantoprazole once the relevant patents expire. They often file their own patents for alternative manufacturing processes or improved formulations that do not infringe existing patents.
- Specialty Pharmaceutical Companies: Some companies may hold patents for specific delivery systems or modified-release formulations of pantoprazole, aiming to differentiate their products.
Types of Patents in the Landscape:
- Active Ingredient Patents: These are the foundational patents that protect the pantoprazole molecule itself. These patents have largely expired in most major markets, including Argentina, allowing for generic entry.
- Process Patents: Patents like AR108616 fall into this category. They protect specific methods of manufacturing pantoprazole or its pharmaceutical compositions. The expiration of these patents can also open doors for generics to adopt similar, non-infringing processes.
- Formulation Patents: These patents cover specific drug delivery systems, excipient combinations, or dosage forms designed to improve efficacy, stability, or patient compliance.
- Polymorph Patents: Pantoprazole, like many APIs, can exist in different crystalline forms (polymorphs). Patents covering specific, stable, and therapeutically advantageous polymorphs can extend market exclusivity.
Patent Expiration and Generic Entry:
The expiration of foundational patents for pantoprazole has led to a competitive generic market in Argentina. However, secondary patents, such as process patents like AR108616, can still provide a degree of protection and influence the market by dictating specific manufacturing methods. Generics manufacturers must carefully navigate these secondary patents to avoid infringement.
Infringement Considerations:
Companies seeking to market pantoprazole products in Argentina must conduct thorough freedom-to-operate (FTO) analyses. This involves:
- Identifying Relevant Patents: Searching patent databases for active patents related to pantoprazole manufacturing, formulations, and polymorphs.
- Claim Construction: Analyzing the claims of identified patents to understand their exact scope.
- Comparing Own Product/Process: Determining if the intended product or manufacturing process falls within the scope of any active patent claims.
Process patents like AR108616 are particularly relevant for manufacturers as they dictate how the drug product is made. If a generic manufacturer uses a process substantially similar to that claimed in AR108616, they risk infringement.
How Does AR108616 Compare to Other Pantoprazole Patents?
Patent AR108616's significance is best understood by comparing its claims and scope to other pantoprazole-related patents that may exist or have existed in Argentina. The primary differentiating factor for AR108616 is its focus on a specific process for manufacturing a stable and well-dissolving solid pharmaceutical composition of pantoprazole.
Comparison Points:
- Active Ingredient Patents: These are the broadest and earliest patents. They protect the pantoprazole molecule itself. AR108616 is a secondary patent that claims a method of making a product from pantoprazole, not the API itself. These foundational patents have expired, allowing generic synthesis of the molecule.
- Early Formulation Patents: Initial formulation patents might have focused on creating stable dosage forms using conventional excipients and methods. AR108616 likely builds upon this by proposing a specific method that overcomes certain stability or dissolution challenges not adequately addressed by earlier, broader formulation patents. It offers a refined approach to achieving desired product characteristics.
- Polymorph Patents: If other patents in Argentina cover specific crystalline forms of pantoprazole, AR108616 would be distinct if its process leads to a particular polymorph or if its claims are independent of the polymorphic form. A process patent might be used to produce a known polymorph more efficiently or with greater purity. Conversely, a polymorph patent would protect the unique crystalline structure, regardless of the synthesis route, as long as it is the claimed polymorph.
- Other Process Patents: AR108616 would be compared against other pantoprazole process patents. The claims of AR108616 would need to be meticulously analyzed against any other granted process patents to determine novelty and inventive step. If other process patents exist, they might claim different steps, different excipients, or different outcomes (e.g., targeting a different impurity profile or a different drug release mechanism). AR108616's distinctiveness lies in the specific sequence, conditions, and components detailed in its claims for achieving its stated advantages.
- Patent Expiration Dates: The relative expiration dates of patents are crucial. AR108616's strength and relevance in the current landscape depend on its own expiration date and whether it has been granted protection for a significant period following the expiration of more fundamental patents. Patents with later expiration dates provide longer-term market exclusivity or influence.
Strategic Implications:
For generic manufacturers, AR108616 represents a potential hurdle. If they wish to employ a manufacturing process that closely mirrors the steps and conditions described in the claims of AR108616, they would need to secure a license or develop a non-infringing alternative process. This often involves significant R&D investment to design a process that achieves comparable product quality and stability without crossing the boundaries defined by AR108616.
The existence of AR108616 suggests that its assignee has identified a specific technical problem in pantoprazole manufacturing and has devised a novel solution. This solution, protected by the patent, is intended to provide commercial advantages, such as superior product quality or manufacturing efficiency, for a defined period.
Potential for Infringement and Freedom-to-Operate Challenges
Companies seeking to develop, manufacture, or market pantoprazole solid pharmaceutical compositions in Argentina face potential infringement risks related to patent AR108616. A comprehensive Freedom-to-Operate (FTO) analysis is essential to navigate this landscape.
Sources of Infringement Risk:
- Manufacturing Process: The most direct infringement risk arises from using a manufacturing process that falls within the scope of AR108616's claims. This includes replicating the specific steps, conditions, and potentially excipient combinations detailed in the patent.
- Importation and Sale of Products Made by the Patented Process: Even if a company manufactures a pantoprazole composition outside Argentina using a process that infringes AR108616, importing and selling that product within Argentina can constitute infringement.
- Offers for Sale: Making offers to sell products manufactured using the patented process within Argentina can also be considered infringement.
Key Steps in an FTO Analysis:
- Patent Identification and Monitoring: Actively search patent databases (e.g., INPI, WIPO) for patents and patent applications related to pantoprazole, focusing on process and formulation claims. This includes monitoring for new filings and granted patents.
- Claim Interpretation: Meticulously analyze the wording of each claim in AR108616. This involves understanding the precise meaning of technical terms and the scope of each element within the claim.
- Comparison to Own Activities: Compare the company's intended manufacturing process, formulation, and product characteristics against the interpreted claims of AR108616.
- Direct Infringement: Does the company's process include every element recited in at least one claim of AR108616?
- Doctrine of Equivalents: If direct infringement is not evident, assess whether the company's process performs substantially the same function in substantially the same way to achieve substantially the same result, even if minor differences exist.
- Validity Assessment: If potential infringement is identified, assess the validity of AR108616. This involves examining whether the patent was properly granted, considering prior art and patentability requirements in Argentina. An invalid patent cannot be infringed.
- Design Around Strategies: If infringement risk is high and the patent is deemed valid, consider "designing around" the patent. This involves modifying the company's process or formulation to avoid infringing any of the claims. This requires a deep understanding of the patent's scope to ensure the modifications are effective.
Consequences of Infringement:
- Injunctions: A patent holder can seek court orders to stop infringing activities.
- Damages: Infringers may be liable for monetary damages, often calculated based on lost profits or reasonable royalties.
- Legal Costs: Defending against infringement claims can be expensive.
Given that AR108616 claims a specific manufacturing process for a stable and dissolvable pantoprazole composition, any company looking to enter or expand in the Argentine market with such a product must conduct a thorough FTO analysis to avoid potential legal challenges from the patent holder.
Key Takeaways
Patent AR108616 protects a specific process for manufacturing solid pharmaceutical compositions of pantoprazole, aiming for improved stability and dissolution. Its claims delineate a defined method of production. The Argentine patent landscape for pantoprazole is competitive, with AR108616 representing a potential barrier for generic manufacturers seeking to employ similar manufacturing techniques. A robust Freedom-to-Operate analysis is critical for any entity planning to produce or market pantoprazole in Argentina to assess and mitigate infringement risks associated with this process patent.
FAQs
-
What is the primary advantage claimed by the process in AR108616?
The primary advantages claimed by the process in AR108616 are improved stability and optimized dissolution of solid pharmaceutical compositions containing pantoprazole.
-
Does AR108616 claim the pantoprazole molecule itself?
No, AR108616 is a process patent and does not claim the pantoprazole molecule itself. It claims a method for preparing a solid pharmaceutical composition containing pantoprazole.
-
What are the implications of AR108616 for generic pantoprazole manufacturers in Argentina?
Generic manufacturers must ensure their manufacturing processes do not infringe on the specific claims of AR108616. They may need to develop alternative, non-infringing processes or license the patent.
-
How long is patent AR108616 likely to be in force?
The term of a patent in Argentina is generally 20 years from the filing date. The exact remaining term would depend on the original filing date of AR108616, which needs to be verified with the Argentine patent office (INPI).
-
What is the first step a company should take to assess infringement risk regarding AR108616?
The first step is to conduct a thorough Freedom-to-Operate (FTO) analysis, which involves identifying the patent, carefully interpreting its claims, and comparing them against the company's intended manufacturing process and product.
Citations
[1] Argentine National Institute of Industrial Property (INPI) Patent Database. (n.d.). AR108616. Retrieved from [INPI Website - Specific Patent Search Functionality] (Note: Direct URL to specific patent documents is often dynamic and requires specific search parameters. Public access interfaces are available on INPI's official website).
